摘要
目的 探讨经尿道膀胱肿瘤电切术后吉西他滨+表柔比星灌注化疗在非肌层浸润性膀胱癌患者中的应用效果。方法 根据化疗药物的不同将97例非肌层浸润性膀胱癌患者分为观察组(n=50)和对照组(n=47),观察组患者经尿道膀胱肿瘤电切术后给予吉西他滨+表柔比星灌注化疗,对照组患者术后给予表柔比星灌注化疗。比较两组患者的临床疗效、Dickkopf相关蛋白1(DKK-1)水平、人类软骨糖蛋白39(YKL-40)水平、不良反应发生情况和预后情况。结果 观察组患者的治疗总有效率为86.00%,高于对照组患者的68.09%,差异有统计学意义(P﹤0.05)。治疗后,两组患者DKK-1、YKL-40水平均低于本组治疗前,且观察组患者DKK-1、YKL-40水平均低于对照组,差异均有统计学意义(P﹤0.05)。观察组患者不良反应总发生率为16.00%,与对照组患者的10.64%比较,差异无统计学意义(P﹥0.05)。随访1年,观察组患者的总生存率为88.00%,明显高于对照组患者的55.32%,差异有统计学意义(P﹤0.01)。结论 经尿道膀胱肿瘤电切术后吉西他滨+表柔比星灌注化疗能够有效改善临床疗效,降低DKK-1、YKL-40水平,改善预后。
Objective To investigate the effect of gemcitabine plus epirubicin infusion chemotherapy in patients with non-muscle invasive bladder cancer after transurethral resection of bladder tumor. Method A total of 97 patients with non-muscle invasive bladder cancer were divided into observation group(n=50) and control group(n=47) according to different chemotherapy drugs. The patients in the observation group were given gemcitabine plus epirubicin infusion chemotherapy after the transurethral resection of bladder tumor, and the patients in the control group were given epirubicin infusion chemotherapy after the operation. The clinical efficacy, dickkopf-related protein 1(DKK-1) level, human cartilage glycoprotein-39(YKL-40) level, adverse events, and prognosis were compared between the two groups. Result The total effective rate of treatment in the observation group was 86.00%, which was higher than 68.09% in the control group, and the difference was statistically significant(P<0.05). After the treatment, the levels of DKK-1 and YKL-40 in the two groups were lower than those before the treatment, and the levels of the two indicators in the observation group were lower than those in the control group, and the differences were statistically significant(P<0.05). The total incidence of adverse reactions in the observation group was 16.00%, and there was no significant difference compared with 10.64%in the control group(P>0.05). Following up for one year, the total survival rate of patients in the observation group was88.00%, which was significantly higher than 55.32% in the control group(P<0.01). Conclusion After transurethral resection of bladder tumor, gemcitabine + epirubicin infusion chemotherapy can effectively improve the clinical efficacy, reduce the levels of DKK-1 and YKL-40, and improve the prognosis.
作者
吴洵柱
肖尚文
胡正鲜
WU Xunzhu;XIAO Shangwen;HU Zhengxian(Department of Urology,Ankang Hospital of Traditional Chinese Medicine,Ankang 725000,Shaanxi,China)
出处
《癌症进展》
2023年第3期283-285,289,共4页
Oncology Progress
关键词
非肌层浸润性膀胱癌
经尿道膀胱肿瘤电切术
吉西他滨
表柔比星
临床疗效
non-muscle invasive bladder cancer
transurethral resection of bladder tumor
gemcitabine
epirubicin
clinical efficacy
